Getting Started

  • Daria Mochly-RosenEmail author
  • Kevin Grimes
Part of the SpringerBriefs in Pharmaceutical Science & Drug Development book series (BRIEFSPSDD)


In recent decades, we in academia have focused on advancing scientific understanding through basic research and counted on the biopharmaceutical industry to translate promising discoveries into new therapeutics. Given the recent developments, however, this paradigm needs to change. Pharmaceutical companies have drastically cut their research budgets and basic research staffs to decrease costs and improve short-term profits. Additionally, the number of biotechnology venture funds has contracted, especially those that invest in new biotechnology start-up companies. As a result, we can expect that fewer novel drug programs will originate in the biopharmaceutical sector. Academic inventors can and should step in to fill this gap in the discovery pipelines. But we often lack the expertise and resources to advance our projects through this applied science stage of drug discovery and development. This chapter introduces the process of drug development and highlights some of the important first steps: understanding the clinical needs, developing a target product profile (which defines the new drug’s essential characteristics), and adopting a project management approach. These essential steps not only increase the likelihood of success, but can also help decrease both the cost and time required to accomplish our goal. Translating discoveries from bench to bedside is a challenging, but incredibly rewarding process, allowing us to advance scientific discovery and ensure that our government-funded research translates into improved health for our society.


Amyotrophic Lateral Sclerosis Active Pharmaceutical Ingredient Good Laboratory Practice Gantt Chart Contract Research Organization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Frearson JA, Wyatt PG, Gilbert IH, Fairlamb AH (2007) Target assessment for antiparasitic drug discovery. Trends Parasitol 23(12):589–595. doi: 10.1016/ PubMedCrossRefGoogle Scholar
  2. 2.
    Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R (2009) Advancing drug innovation for neglected diseases—criteria for lead progression. PLoS Negl Trop Dis 3(8):e440. doi: 10.1371/journal.pntd.0000440 PubMedCrossRefGoogle Scholar
  3. 3.
    Kennedy A (2008) Pharmaceutical project management, vol 182, 2nd edn, Drugs and the pharmaceutical sciences. Informa Healthcare, New YorkGoogle Scholar
  4. 4.
    Linberg SE (2006) Expediting drugs and biologics development, 3rd edn. Parexel International Corporation, Waltham, MA, USAGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Chemical and Systems BiologyStanford University School of MedicineStanfordUSA
  2. 2.Chemical and Systems BiologyStanford University School of MedicineStanfordUSA

Personalised recommendations